GDT | Jotup

Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Retrieved on:

水曜日, 5月 29, 2024

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
Preliminary results of this first patient in the second cohort obtained six weeks after beginning treatment show a favorable safety and tolerability profile, while imaging shows promising early efficacy for the Deltacel™ treatment.
Additionally, this patient experienced quality-of-life benefits from Deltacel treatment including stopping their previous need for prescription pain medication.
“These encouraging clinical findings represent a strong start to the second cohort in our Deltacel-01 trial.

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site

Retrieved on:

月曜日, 5月 20, 2024

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
UPMC is a world-renowned healthcare system that employs some of the nation’s top clinicians and medical researchers.
The lead principal investigator for Deltacel-01, Jason J. Luke, MD, FACP, will also serve as principal investigator at the UPMC site.
We expect to activate one more clinical trial site later this quarter and to begin enrolling patients at UPMC this summer,” said Pietro Bersani, Chief Executive Officer of Kiromic.

GDT Recognized by Palo Alto Networks as a NextWave Diamond Innovator

Retrieved on:

月曜日, 5月 13, 2024

Diamond, Computer security, Automation, Risk, DTK Computer, SVP, GDT, Market, NextWave Wireless

DALLAS, May 13, 2024 /PRNewswire/ -- General Datatech (GDT) today announced it has become a Palo Alto Networks NextWave Diamond Innovator.

Key Points:

DALLAS, May 13, 2024 /PRNewswire/ -- General Datatech (GDT) today announced it has become a Palo Alto Networks NextWave Diamond Innovator.
GDT joins a select group of channel partners who have met the Diamond Innovator performance, capabilities, and business requirements of the Palo Alto Networks NextWave Partner Program .
As a Palo Alto Networks Diamond Innovator, GDT offers deep expertise in delivering robust, end-to-end cybersecurity solutions that empower customers with the visibility, flexibility, and automation needed to strengthen their security posture from the endpoint, across the network, and into the cloud.
"Our Diamond Innovator NextWave partners have deep Palo Alto Networks expertise to help solve complex security challenges with robust solutions and services.

GDT Among Less than 1% of Cisco Partners to Achieve Advanced Customer Experience Specialization

Retrieved on:

木曜日, 5月 9, 2024

Investment, Internet of things, Certification, Specialization, GDT, Software, Architecture

DALLAS, May 9, 2024 /PRNewswire/ -- General Datatech (GDT) announced that it has achieved Cisco Advanced Customer Experience Specialized Certification, placing the global IT solutions provider amongst fewer than 1% of Cisco partners in the US to have earned the certification.

Key Points:

DALLAS, May 9, 2024 /PRNewswire/ -- General Datatech (GDT) announced that it has achieved Cisco Advanced Customer Experience Specialized Certification, placing the global IT solutions provider amongst fewer than 1% of Cisco partners in the US to have earned the certification.
The Cisco Advanced Customer Experience Specialized Certification validates GDT's industry-leading capabilities, best-practice methodologies, and proven track record of accelerating business outcomes.
This customer-focused certification is open to Cisco partners demonstrating deep software expertise through Cisco architecture specializations across networking, collaboration, security, data center, and service provider technologies.
To meet stringent requirements, GDT completed advanced training and certifications, provided customer references, and underwent rigorous validation for customer success requirements in resourcing, methodology, and platforms.

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Retrieved on:

水曜日, 4月 24, 2024

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces consistent favorable safety, tolerability, and efficacy from follow-up visits of the first cohort of three patients enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
Imaging scans from Patient 2 also showed no brain metastases, confirming findings from that patient’s six-week follow-up visit.
The four-month follow-up for the second and third patients on trial is scheduled for June.
"We are highly encouraged by the initial outcomes from the first three patients in our Deltacel-01 Phase 1 clinical trial.

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Retrieved on:

火曜日, 4月 2, 2024

Software, Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, SMC, Safety, Lung cancer, Patient, BHCC, PET/CT, OTCQB, Cancer, MRI, NSCLC, GDT

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial.
Preliminary imaging results for this last patient in the first cohort, obtained six weeks after beginning treatment, show a favorable safety and tolerability profile, and promising early efficacy for the Deltacel™ treatment.
Additionally, the Deltacel-01 Safety Monitoring Committee (SMC) convened to analyze all preliminary patient data received to date and to determine the next phase of the trial.
This unanimous recommendation was based on encouraging preliminary data supporting Deltacel™ safety and tolerability, and evidence of anti-tumor activity.

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial

Retrieved on:

火曜日, 3月 19, 2024

Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Principal, Safety, Lung cancer, Patient, BHCC, OTCQB, MRI, Traffic barrier, NSCLC, GDT, Medical imaging

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial.

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial.
Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
Preliminary results obtained six weeks from the beginning of treatment show Deltacel’s efficacy in controlling tumor growth, as well as favorable safety and tolerability.
Kiromic expects to announce initial safety, tolerability, and preliminary efficacy results from the third patient enrolled in Deltacel-01 by the end of March.

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Retrieved on:

金曜日, 3月 1, 2024

Oncology, Health, Clinical Trials, Research, Science, Biotechnology, NSCLC, OTCQB, Lung cancer, GDT, MSHA, Safety, Patient, Medical imaging

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).

Key Points:

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with non-small cell lung cancer (NSCLC).
“Virginia Oncology Associates is known for its excellence in oncology-focused research and patient care, and we are delighted to add them as the second Deltacel-01 clinical trial site.
The site initiation process at Virginia Oncology Associates has been completed and patient enrollment is expected to begin in April, following receipt of preliminary results from the first three-patient cohort in Deltacel-01.
Kiromic also announces that the third patient in Deltacel-01 completed treatment at the Beverly Hills Cancer Center on February 21.

General Datatech (GDT) Adds Industry Veteran to Executive Leadership Team

Retrieved on:

水曜日, 12月 27, 2023

Interim management, Interim, Growth, GDT, Haughey, Certification, Private sector, Management

Haughey brings an impressive portfolio of experience to GDT, including 20 years of public accounting and management consulting and 10 years in the private sector.

Key Points:

Haughey brings an impressive portfolio of experience to GDT, including 20 years of public accounting and management consulting and 10 years in the private sector.
In his most recent leadership role at Riveron Consulting, LLC, Haughey helped drive efficiencies, operational changes, and data-driven reporting that led to top-line and bottom-line growth for his clients.
"It's an incredible time to be a part of GDT," adds Haughey.
"The recent Great Place to Work™ certification in both the U.S. and India is just one example of GDT's workplace culture and industry reputation.

General Datatech (GDT) is Great Place to Work® Certified™ in US and India

Retrieved on:

火曜日, 12月 12, 2023

Great Places, Certification, Employee resource group, Cisco, Culture, American Express, European Innovation Council, Accenture, GDT, Workplace, Hulu, Management

DALLAS, Dec. 12, 2023 /PRNewswire/ -- Global IT solutions provider General Datatech (GDT) is proud to announce that both their U.S. and India offices are Great Place to Work® Certified™.

Key Points:

DALLAS, Dec. 12, 2023 /PRNewswire/ -- Global IT solutions provider General Datatech (GDT) is proud to announce that both their U.S. and India offices are Great Place to Work® Certified™.
Great Place To Work Certification recognizes employers who create an outstanding employee experience.
Ninety one percent of employees at GDT say it's a great place to work compared to 57% of employees at a typical U.S.-based company.
The Great Place to Work Trust Index Survey measures individual employee experiences on five dimensions of a high-trust company culture.